EstroVantage EM®

EstroVantage EM®

Estrogen Modulator

90 Vegetarian Capsules ( SKU: 9672, NPN: 80044252 )

Benefits

  • Offers a full array of protective compounds from cruciferous vegetables, including I3C, DIM, and sulforaphane
  • Provides a unique blend of botanicals that improve estrogen metabolism, shifting away from carcinogenic metabolites
  • Supports detoxification of a variety of environmental toxins as well as naturally produced hormones by enhancing phase 1 and phase 2 liver enzymes
  • Contains botanicals with potent anti-inflammatory activity 
  • Suitable for vegetarians/vegans 

Feature Summary

EstroVantage EM provides a comprehensive formula of plant-based compounds that improve the metabolism of estrogen and its metabolites. Cruciferous vegetables contain a variety of glucosinolates, which some studies have associated with a reduction in cancer incidence when consumed in greater amounts, most likely by causing a shift in metabolism to less carcinogenic estrogen metabolites.1,2 EstroVantage EM contains indole-3-carbinol (I3C) and its metabolite 3,3’-diindolylmethane (DIM), as well as sulforaphane from broccoli powder, all of which have been linked to lower rates of neoplastic changes and a more favourable estrogen profile.3-6 Not only do these glucosinolates improve estrogen metabolism, they also reduce inflammation by targeting key signalling molecules, such as Nrf2 and NF-κB.7,8 

EstroVantage EM also includes other potent plant compounds that reduce inflammation and block carcinogenic pathways. Silymarin, a milk thistle extract, down-regulates gene products involved in the proliferation of tumour cells, along with their invasion, angiogenesis, and metastasis. In addition, it enhances glucuronidation and maintains glutathione levels.9-11 This unique combination provides green tea polyphenols, lycopene (tomato extract), turmeric and rosemary extracts, as well as calcium D-glucarate, all of which have been shown to favourably shift estrogen metabolism and reduce carcinogenic risk.12-14 Most recently, a randomized, double-blind, placebo-controlled crossover study demonstrated that taking this formula led to markedly higher urinary levels of the protective 2-OHE1 estrogen metabolite and lower levels of the more dangerous 16α-OHE1 estrogen metabolite in premenopausal women.Most recently, a randomized, double-blind, placebo-controlled crossover study demonstrated that taking this formula led to markedly higher urinary levels of the protective 2-OHE1 estrogen metabolite and lower levels of the more dangerous 16α-OHE1 estrogen metabolite in premenopausal women.15

Medicinal Ingredients

Each Vegetarian Capsule Contains:
Calcium D-Glucarate (d-Glucaric Acid Calcium Salt) 75 mg
Indole-3-Carbinol (3-Hydroxymethylindole) 75 mg
Green Tea Extract (Camellia sinensis) (leaf) (80% Catechins, 45% EGCG*, <1% Caffeine) 50 mg
Tomato Extract (Lycopersicon esculentum) (fruit) (5% Lycopene) 50 mg
Broccoli Powder (Brassica oleracea var. italica) (aerial) (0.36% Sulforaphane) 27.5 mg
DIM (3,3’-Diindolylmethane) 25 mg
Turmeric Extract (Curcuma longa) (rhizome) (95% Curcuminoids) 25 mg
Milk Thistle Extract (Silybum marianum) (seed) (50–60% Silymarin) 25 mg
Rosemary 6:1 Extract (Rosmarinus officinalis) (leaf) 12.5 mg
* Epigallocatechin-3-gallate

Non-Medicinal Ingredients

Vegetarian capsule (carbohydrate gum [cellulose], purified water), microcrystalline cellulose, vegetable grade magnesium stearate (lubricant), silica.

Dosage:

3 capsules once per day with food or as directed by a health care practitioner. Consult a health care practitioner for use beyond 12 weeks.

Warnings:

Do not use if you are pregnant or breastfeeding, or if you have iron deficiency. Consult a health care practitioner if you have gallstones or a bile duct obstruction, stomach ulcers or excess stomach acids, or if you are taking any medications. Consult a health care practitioner prior to use if you are attempting to conceive, have low estrogen or symptoms of low estrogen, have or are pre-disposed to cancer, are taking antiplatelet medication or blood thinners, or have a liver disease. Stop use and consult a health care practitioner if you develop symptoms of liver trouble such as yellowing of the skin/eyes (jaundice), stomach pain, dark urine, sweating, nausea, unusual tiredness and/or loss of appetite. Rare, unpredictable cases of liver injury associated with products containing green tea extract have been reported (in Canada and internationally). Hypersensitivity/allergy is known to occur, in which case discontinue use. Keep out of reach of children.

Allergens:

Contains no artificial colours, preservatives, or sweeteners; no dairy, sugar, wheat, gluten, yeast, soy, egg, fish, shellfish, animal products, salt, tree nuts, or GMOs. Suitable for vegetarians/vegans. Sealed for your protection. Do not use if seal is broken. For freshness, store in a cool, dry place.

Drug Interactions

Do not take with warfarin.16

  1. Lin, T., Zirpoli, G. R., McCann, S. E., et al. (2017). Trends in cruciferous vegetable consumption and associations with breast cancer risk: a case-control study. Current Developments in Nutrition, 1(8), e000448.
  2. Mokbel, K., & Mokbel, K. (2019). Chemoprevention of breast cancer with vitamins and micronutrients: a concise review. In Vivo, 33(4), 983-97.
  3. Zhang, N. Q., Ho, S. C., Mo, X. F., et al. (2018). Glucosinolate and isothiocyanate intakes are inversely associated with breast cancer risk: a case-control study in China. British Journal of Nutrition, 119(8), 957-64.
  4. Thomson, C. A., Chow, H. H. S., Wertheim, B. C., et al. (2017). A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. Breast Cancer Research and Treatment, 165(1), 97-107.
  5. Ramirez, M. C., & Singletary, K. (2009). Regulation of estrogen receptor alpha expression in human breast cancer cells by sulforaphane. Journal of Nutritional Biochemistry, 20, 195-201.
  6. Bradlow, H. L., Michnovicz, J. J., Halper, M., et al. (1994). Long-term responses of women to indole-3-carbinol or a high fiber diet. Cancer Epidemiology, Biomarkers & Prevention, 3(7), 591-5.
  7. Esteve, M. (2020). Mechanisms underlying biological effects of cruciferous glucosinolate-derived isothiocyanates/indoles: a focus on metabolic syndrome. Frontiers in Nutrition, 7, 111.
  8. Bauman, J. E., Zang, Y., Sen, M., et al. (2016). Prevention of carcinogen-induced oral cancer by sulforaphane. Cancer Prevention Research (Philadelphia), 9(7), 547-57.
  9. Agarwal, R., Agarwal, C., Ichikawa, H., et al. (2006). Anticancer potential of silymarin: from bench to bed side. Anticancer Research, 26(6B), 4457-98.
  10. Vargas-Mendoza, N., Madrigal-Santillán, E., Morales-Gonzalez, A., et al. (2014). Hepatoprotective effect of silymarin. World Journal of Hepatology, 6(3), 144-9.
  11. Binienda, A., Ziolkowska, S., & Pluciennik, E. (2020). The anticancer properties of silibinin: its molecular mechanism and therapeutic effect in breast cancer. Anticancer Agents in Medicinal Chemistry, 20(15), 1787-96.
  12. King-Batoon, A., Leszczynska, J. M., & Klein, C. B. (2008). Modulation of gene methylation by genistein or lycopene in breast cancer cells. Environmental and Molecular Mutagenesis, 49(1), 36-45.
  13. Dwivedi, C., Heck, W. J., Downie, A. A., et al. (1990). Effect of calcium glucarate on beta-glucuronidase activity and glucarate content of certain vegetables and fruits. Biochemical Medicine and Metabolic Biology, 43(2), 83-92.
  14. McGrowder, D. A., Miller, F. G., Nwokocha, C. R., et al. (2020). Medicinal herbs used in traditional management of breast cancer: mechanisms of action. Medicines (Basel), 7(8), 47.
  15.  Green, T., See, J., Schauch, M., et al. (2022). A randomized, double-blind, placebo-controlled, cross-over trial to evaluate the effect of EstroSense® on 2-hydroxyestrone:16α-hydroxyestrone ratio in premenopausal women. J Complement Integr Med, 10.1515/jcim-2022-0301. Advance online publication.
  16. Brantley, S. J., Oberlies, N. H., Kroll, D. J., et al. (2010). Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. Journal of Pharmacology and Experimental Therapeutics, 332, 1081-7.